Funding supports commercial launch of novel fluorescence image-guided surgery system
OnLume Surgical, a Wisconsin-based medical device company developing novel imaging systems for use during surgery, announced the completion of its Series A funding to assist its plans for commercial launch.
OnLume raised over $7 Million in this financing, adding to a $2 Million Phase II SBIR grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), awarded in late 2020.
“The completion of the Series A financing, plus the Phase II grant from NCI, provides the resources for important milestones ahead during the next 24 months,” stated James A. Bowman, OnLume’s Chief Executive Officer. “These activities include commercial launch into our first market vertical and progress on other market opportunities.”
“This achievement highlights the promise of OnLume’s patented technology in the field of fluorescence-guided surgery, which illuminates critical anatomy in real-time during surgery to optimize precision, helping to improve patient outcomes, reduce morbidity and reduce costs,” added Mr. Bowman.
This Series A financing was led by Cambridge Investment Group (Luzich Partners LLC) and participation included WARF Ventures (Wisconsin Alumni Research Foundation) and Wisconsin Investment Partners (WIP).
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.